论文部分内容阅读
目的探讨乙型肝炎病毒(HBV)感染与弥漫大B细胞淋巴瘤(DLBCL)临床、病理及预后的关系。方法采用酶联免疫吸附试验(ELISA)检测2004年1月至2013年1月该院收治的150例DLBCL患者的乙肝5项和肝功能,并选取同期住院的其他肿瘤患者150例及门诊健康体检者150例作为对照。结果 DLBCL患者乙型肝炎表面抗原(HBs Ag)的阳性率(22.7%)显著高于其他肿瘤组患者(9.3%)和健康对照组(8.0%)(P<0.05)。HBs Ag阳性组及HBs Ag阴性组DLBCL临床分期、肝脾受累、乳酸脱氢酶(LDH)含量、结节外受累区域和国际预后指数评分(IPI)差异具有统计学意义(P<0.05),且二组患者化疗前后肝功能损伤情况比较亦有统计学差异(P<0.05)。HBs Ag阴性组治疗完全缓解率及生存期均显著高于HBs Ag阳性组(P<0.05)。结论 DLBCL患者HBs Ag阳性率显著高于其他恶性肿瘤患者及健康对照,且HBV感染与DLBCL患者临床病理特征及预后相关。
Objective To investigate the relationship between hepatitis B virus (HBV) infection and the clinical, pathological and prognosis of diffuse large B cell lymphoma (DLBCL). Methods Enzyme-linked immunosorbent assay (ELISA) was used to detect hepatitis B and liver function in 150 patients with DLBCL admitted to our hospital from January 2004 to January 2013. 150 patients with other cancer patients in hospital and out-patient health examination 150 cases as a control. Results The positive rate of HBsAg in DLBCL patients was significantly higher than that in other tumor patients (9.3%) and healthy controls (22.7% vs 8.0%, P <0.05). The clinical stages, liver and spleen involvement, lactate dehydrogenase (LDH), extranodal involvement, and international prognostic index (DLI) of DLBCL in HBsAg-positive and HBsAg-negative groups were significantly different (P <0.05) There was also a statistically significant difference in liver function damage between the two groups before and after chemotherapy (P <0.05). The complete remission rate and survival of HBsAg-negative group were significantly higher than that of HBsAg-positive group (P <0.05). Conclusions The positive rate of HBsAg in patients with DLBCL is significantly higher than those in other malignant tumors and healthy controls. HBV infection is associated with the clinicopathological features and prognosis of patients with DLBCL.